1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €67.98 (+2.30%). The median is €67.98 (+2.30%).
| Buy |
3 |
| Hold |
4 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -20.44M | 114.20% |
| EBITDA | -20.27M | 112.71% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.39B |
Number of shares | 20.49M |
52-week high/low | €68.16 - €8.93 |
| Dividends | No |
Beta | 2.65 |
P/E ratio | -16.77 |
PEG ratio | -0.43 |
P/B ratio | 9.96 |
P/S ratio | 0.00 |
Company profile
Forte Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium in den Vereinigten Staaten. Es entwickelt das Programm FB-102, das verschiedene Autoimmunkrankheiten wie Vitiligo und Alopecia areata behandelt. Der Hauptsitz des Unternehmens befindet sich in Dallas, Texas.
| Name | Forte Biosciences Inc Ordinary Shares |
| CEO | Paul A. Wagner |
| Website | |
| IPO | 04/13/2017 |
| Employees | 23 |
